2 Stocks Lightning Up Trading Screens After Earnings
Health Management Associates Inc. (NYSE:HMA) reported net income above Wall Street’s expectations for the fourth quarter. Net income for the hospital rose to $30.8 million (13 cents per share) vs. $28.2 million (11 cents per share) in the same quarter a year earlier. This marks a rise of 9.5% from the year earlier quarter. Revenue rose 17.6% to $1.58 billion from the year earlier quarter. Health Management Associates Inc. reported adjusted net income of 26 cents per share. By that measure, the company beat the mean estimate of 20 cents per share. Analysts were expecting revenue of $1.58 billion.
“We are pleased to report another year of record revenues and strong earnings as we continue to successfully execute our operating and partnership strategies,” said Gary D. Newsome, Health Management’s President and Chief Executive Officer. “By continuing to focus our efforts on the fundamentals – investment in innovative services and strategic partnerships, recruitment of physicians and leadership talent, adherence to effective cost control measures and development of our very active partnership pipeline, we are looking forward to 2012 as we seek to enable America’s best local health care.”
Competitors to Watch: Community Health Systems (NYSE:CYH), Universal Health Services, Inc. (NYSE:UHS), Tenet Healthcare Corp. (NYSE:THC), HCA Holdings Inc (NYSE:HCA), MedCath Corporation (NASDAQ:MDTH), SunLink Health Systems, Inc. (AMEX:SSY), LifePoint Hospitals, Inc. (NASDAQ:LPNT), Dynacq Healthcare, Inc. (NASDAQ:DYII), Select Medical Hldgs. Corp. (NYSE:SEM), and HEALTHSOUTH Corp. (NYSE:HLS).
Seattle Genetics, Inc. (NASDAQ:SGEN) narrowed its loss in the fourth quarter. Loss narrowed to $27.2 million (loss of 24 cents per diluted share) from $34.5 million (loss of 34 cents per share) in the same quarter a year earlier. Revenue rose more than sixfold to $48.9 million from the year earlier quarter. Seattle Genetics, Inc. beat the mean analyst estimate of a loss of 30 cents per share. It beat the average revenue estimate of $39.1 million.
“We are pleased with the successful launch of ADCETRIS and our execution in bringing this drug to patients in need,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Seattle Genetics. “Our commercialization initiatives continue to focus on expanding awareness of ADCETRIS among oncologists, particularly in the community setting, and ensuring an efficient reimbursement process.”
Competitors to Watch: Pfizer Inc. (NYSE:PFE), Bristol Myers Squibb Co. (NYSE:BMY), Biogen Idec Inc. (NASDAQ:BIIB), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Genzyme Corporation (NASDAQ:GENZ), Micromet Inc. (NASDAQ:MITI), Allos Therapeutics, Inc. (NASDAQ:ALTH), Cephalon, Inc. (NASDAQ:CEPH), Celgene Corporation (NASDAQ:CELG), and ImmunoGen, Inc. (NASDAQ:IMGN).
To contact the reporter on this story: Derek Hoffman at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com